ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Director Sells $1,088,035.00 in Stock

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Director Peter A. Thompson sold 83,695 shares of the stock in a transaction on Monday, August 26th. The shares were sold at an average price of $13.00, for a total transaction of $1,088,035.00. The sale was disclosed in a legal filing with the SEC, which is available through this link.

ARS Pharmaceuticals Price Performance

Shares of SPRY stock traded down $0.22 during mid-day trading on Wednesday, hitting $13.74. The company had a trading volume of 980,976 shares, compared to its average volume of 720,059. The stock’s 50 day moving average price is $10.64 and its 200-day moving average price is $9.46. ARS Pharmaceuticals, Inc. has a 52-week low of $2.55 and a 52-week high of $16.50. The company has a market capitalization of $1.33 billion, a P/E ratio of -26.54 and a beta of 0.87.

ARS Pharmaceuticals (NASDAQ:SPRY) last announced its quarterly earnings results on Tuesday, August 6th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.01). The company had revenue of $0.50 million for the quarter, compared to the consensus estimate of $2.00 million. On average, equities research analysts expect that ARS Pharmaceuticals, Inc. will post -0.66 earnings per share for the current year.

Analysts Set New Price Targets

SPRY has been the subject of a number of recent research reports. Raymond James raised shares of ARS Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and lifted their price target for the company from $18.00 to $22.00 in a research report on Tuesday, August 13th. Cantor Fitzgerald initiated coverage on shares of ARS Pharmaceuticals in a research report on Tuesday, August 20th. They set an “overweight” rating and a $30.00 price target for the company. Finally, Leerink Partners lifted their price target on shares of ARS Pharmaceuticals from $19.00 to $20.00 and gave the company an “outperform” rating in a research report on Monday, August 12th. Five equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $22.75.

Institutional Investors Weigh In On ARS Pharmaceuticals

Large investors have recently bought and sold shares of the business. RA Capital Management L.P. grew its holdings in shares of ARS Pharmaceuticals by 14.8% in the first quarter. RA Capital Management L.P. now owns 10,860,977 shares of the company’s stock worth $110,999,000 after purchasing an additional 1,401,299 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of ARS Pharmaceuticals by 37.0% in the first quarter. Vanguard Group Inc. now owns 2,886,455 shares of the company’s stock worth $29,500,000 after purchasing an additional 779,969 shares during the last quarter. ClariVest Asset Management LLC bought a new position in shares of ARS Pharmaceuticals in the first quarter worth about $2,790,000. Jacobs Levy Equity Management Inc. grew its holdings in shares of ARS Pharmaceuticals by 1,280.5% in the first quarter. Jacobs Levy Equity Management Inc. now owns 277,706 shares of the company’s stock worth $2,838,000 after purchasing an additional 257,589 shares during the last quarter. Finally, Franklin Resources Inc. grew its holdings in shares of ARS Pharmaceuticals by 5.9% in the fourth quarter. Franklin Resources Inc. now owns 4,098,497 shares of the company’s stock worth $22,460,000 after purchasing an additional 229,988 shares during the last quarter. Institutional investors own 68.16% of the company’s stock.

ARS Pharmaceuticals Company Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.